trial · primary record
Samuraciclib
Resectable Pancreatic Ductal Adenocarcinoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 15 |
| Primary completion | 2027-11-01 |
| Primary endpoint | Change in ribonucleic acid polymerase II serine levels |
| Registry ID | NCT07645651 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:39.387Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07645651
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.